Skip to main content
Premium Trial:

Request an Annual Quote

KellBenx Raises $2.5M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Startup biotech firm KellBenx today announced it has raised $2.5 million in an initial funding round.

Four investors participated in the round, three undisclosed venture capital groups and an undisclosed angel investor.

"The funds will be used to launch an [institutional review board]-approved clinical trial and build our Long Island laboratory to analyze the data we are producing," Hassan Bennani, CEO of KellBenx, said in a statement.

Earlier this week, the company announced it had licensed three interleukin biomarkers from Cedars-Sinai Medical Center for the development of tests to predict premature births. The test will be in an ELISA format, but Bennani said that the company is considering next-generation sequencing technologies as well.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.